K
Kenneth Kassler-Taub
Researcher at Lexicon Pharmaceuticals
Publications - 4
Citations - 110
Kenneth Kassler-Taub is an academic researcher from Lexicon Pharmaceuticals. The author has contributed to research in topics: Telotristat ethyl & Carcinoid syndrome. The author has an hindex of 2, co-authored 4 publications receiving 81 citations.
Papers
More filters
Journal ArticleDOI
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Marianne Pavel,David J. Gross,Marta Benavent,Petros Perros,Raj Srirajaskanthan,Richard R.P. Warner,Matthew H. Kulke,Lowell Anthony,Pamela L. Kunz,Dieter Hörsch,Martin O. Weickert,Pablo Lapuerta,Wenjun Jiang,Kenneth Kassler-Taub,Suman Wason,Rosanna Fleming,Douglas Fleming,Rocio Garcia-Carbonero +17 more
TL;DR: Results support the safety and efficacy of telotristat ethyl when added to SSAs in patients with CS diarrhea and significant reductions in u5-HIAA from baseline were observed.
Journal ArticleDOI
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Lowell Anthony,Matthew H. Kulke,Martyn Caplin,Emily K. Bergsland,Kjell Öberg,Marianne Pavel,Dieter Hörsch,Richard R.P. Warner,Thomas M. O'Dorisio,Joseph S. Dillon,Pablo Lapuerta,Kenneth Kassler-Taub,Wenjun Jiang +12 more
TL;DR: By reducing the stool frequency in patients with carcinoid syndrome whose diarrhea is refractory to anticholinergics, such as loperamide and atropine/diphenoxylate, and somatostatin analog dose escalation, improvement in quality of life becomes an achievable goal.
Journal ArticleDOI
Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
Journal ArticleDOI
Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
LuAnn Bundrant,Thomas L. Hunt,Phil Banks,Suma Gopinathan,Kristi A. Boehm,Kenneth Kassler-Taub,Praveen Tyle,Alan Wilson,Chris Warner,Suman Wason +9 more
TL;DR: LX9211 has received fast track designation by the US Food and Drug Administration (US FDA) for neuropathic pain and postherpetic neuralgia (PHN) as mentioned in this paper.